April 30, 2024 – Pfizer Inc. introduced that the U.S. Meals and Drug Administration (FDA) has authorized BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the remedy of adults with reasonable to extreme hemophilia B who’re presently taking issue IX (FIX) prophylaxis remedy or have a present or historical past of life-threatening bleeding has, or has recurrent, extreme spontaneous bleeding, and […]
